Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The end-products of lipid oxidation are a chemically diverse set of small molecules formed during the oxidative degradation (peroxidation) of polyunsaturated fatty acids and other lipid classes. These products — including aldehydes like malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE), and a wide array of related compounds — are highly reactive and capable of forming covalent adducts with DNA, proteins, and cellular membranes. The accumulation of these products mediates oxidative stress, cell damage, and inflammation, and is implicated in several pathologies, including atherosclerosis, neurodegeneration, cancer, and other diseases linked to chronic inflammation and oxidative injury. Because this is a class of reactive molecules, not a discrete entity with a canonical structure, it is not considered a therapeutic target per se but rather a set of damaging metabolites whose formation is ideally prevented or measured as biomarkers of oxidative injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on End-product of lipid oxidation.